<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04717999</url>
  </required_header>
  <id_info>
    <org_study_id>UBP-P02-3001-GBM</org_study_id>
    <nct_id>NCT04717999</nct_id>
  </id_info>
  <brief_title>Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma</brief_title>
  <official_title>Pilot Study of UWNKG2D CAR-T in Treating Patients With Recurrent Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UWELL Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UWELL Biopharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot phase I study to evaluate the safety and efficacy of NKG2D CAR-T cell therapy&#xD;
      in patients with relapsed and/or refractory glioblastoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants who experience a Dose-Limiting Toxicity (DLT)</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the dose safely administered Intratumoral for the treatment of patients with GBM</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as the proportion of subjects with overall response of either complete response (CR) or partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as date of the first NKG2D CAR-T infusion to the date of disease progression per RANO Response Criteria or death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Recurrent Glioblastoma</condition>
  <arm_group>
    <arm_group_label>UWN2D CAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NKG2D CAR-T</intervention_name>
    <description>The NKG2D CAR-T will be administrated via intracerebroventricular injection through an Ommaya catheter. Standard treatments such as temozolomide will be stopped during the infusion of NKG2D CAR-T.</description>
    <arm_group_label>UWN2D CAR-T</arm_group_label>
    <other_name>UWN2D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed glioblastoma multiforme (GBM) and are at first or second&#xD;
             relapse.&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dl, absolute neutrophil count (ANC) ≥ 1,000 cells/µl, platelets ≥&#xD;
             125,000 cells/µl&#xD;
&#xD;
          -  No active infection of HIV, HTLV and Syphilis&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
          -  Adequate hepatic function&#xD;
&#xD;
          -  Adequate cardiac function&#xD;
&#xD;
          -  Adequate venous access for apheresis, and no other contraindications for leukapheresis&#xD;
&#xD;
          -  Voluntary informed consent is given.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Uncontrolled active infection.&#xD;
&#xD;
          -  History of hepatitis B or hepatitis C infection.&#xD;
&#xD;
          -  Previously treatment with any gene therapy products or cell therapy product in past 28&#xD;
             days.&#xD;
&#xD;
          -  Cannot undergo MRI with contrast or SPECT/CT&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Have autoimmune disorders&#xD;
&#xD;
          -  Have active infection or inflammatory disorders&#xD;
&#xD;
          -  Prescreening test results in expansion rate less than 5 folds&#xD;
&#xD;
          -  An allergy to gentamycin and/or streptomycin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cheng-Yi Kuo, PhD</last_name>
    <phone>+886-2-26972200</phone>
    <phone_ext>202</phone_ext>
    <email>jerry.kuo@uwell.com.tw</email>
  </overall_contact>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 16, 2021</study_first_submitted>
  <study_first_submitted_qc>January 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 16, 2021</last_update_submitted>
  <last_update_submitted_qc>January 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

